

Resource Summary Report

Generated by [dkNET](#) on Aug 6, 2026

Brilliant Violet 785(TM) anti-human CD8

RRID:AB_2566201

Type: Antibody

Proper Citation

BioLegend Cat# 344739, RRID:AB_2566201

Antibody Information

URL: http://antibodyregistry.org/AB_2566201

Proper Citation: BioLegend Cat# 344739, RRID:AB_2566201

Target Antigen: CD8

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 785(TM) anti-human CD8

Description: This monoclonal targets CD8

Target Organism: cynomolgus, rhesus, human

Clone ID: Clone SK1

Antibody ID: AB_2566201

Vendor: BioLegend

Catalog Number: 344739

Alternative Catalog Numbers: 344740

Record Creation Time: 20250820T012719+0000

Record Last Update: 20250820T105822+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 785(TM) anti-human CD8.

No alerts have been found for Brilliant Violet 785(TM) anti-human CD8.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Champagne J, et al. (2025) Adoptive T cell therapy targeting an inducible and broadly shared product of aberrant mRNA translation. *Immunity*, 58(1), 247.

Yin Y, et al. (2025) Activated T cells degrade extracellular proteins to enhance effector functions. *Cell reports*, 45(1), 116797.

Abayasiriwardana K, et al. (2025) A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies. *Molecular cancer therapeutics*, 24(7), 976.

Radziszewska A, et al. (2024) Type I interferon and mitochondrial dysfunction are associated with dysregulated cytotoxic CD8+ T cell responses in juvenile systemic lupus erythematosus. *Clinical and experimental immunology*.

Gupta T, et al. (2024) Tracking in situ checkpoint inhibitor-bound target T cells in patients with checkpoint-induced colitis. *Cancer cell*, 42(5), 797.

Park JA, et al. (2021) Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response. *Journal of hematology & oncology*, 14(1), 142.

Webb LV, et al. (2019) Survival of Single Positive Thymocytes Depends upon Developmental Control of RIPK1 Kinase Signaling by the IKK Complex Independent of NF- κ B. *Immunity*, 50(2), 348.